DBV Technologies (DBVT) Cash from Investing Activities Growth (3y) (2023 - 2026)

DBV Technologies (DBVT) Cash from Investing Activities Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn -29.84%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 38.24%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -22.09%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 DBV Technologies 6.06 Bn 5.88 Bn - -20.73%

Historic Data

Download Data
DateValue
Jun 30, 2026 -20.73%
Mar 31, 2026 -109.10%
Dec 31, 2025 -176.02%
Sep 30, 2025 -54.26%
Mar 31, 2025 -237.27%
Dec 31, 2024 54.29%
Sep 30, 2024 -58.98%
Jun 30, 2024 58.97%
Mar 31, 2024 -125.88%
Dec 31, 2023 33.40%
Sep 30, 2023 25.60%
Jun 30, 2023 13.12%
Mar 31, 2023 26.93%